RxDoctor Payments Data

Toby Handler, MD

Urology · Garden City, NYNPI 1891758710

Payments from drug & device makers

$8,234in general payments, 2019–2025

Across 371 payments — averaging $22.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Astellas Pharma US Inc$716
  • Johnson & Johnson$680
  • Sumitomo Pharma America, Inc.$612
  • Amgen$435
  • Urogen Pharma, Inc.$409
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$8,12799%
  • Education$1071%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,234 in reported general payments places this provider in the 75th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$864,480
Medicare patients
1,597
Services billed
33,476

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron236$259,350
MyrbetriqMirabegron191$164,322
Solifenacin Succinate183$24,116
Mirabegron ErMirabegron30$20,681
AndrogelTestosterone12$13,548
Methenamine Hippurate131$13,373
Estradiol124$10,525
Trospium Chloride ErTrospium Chloride27$7,618
PremarinEstrogens, Conjugated15$6,525
Tolterodine Tartrate ErTolterodine Tartrate45$5,267
Oxybutynin Chloride ErOxybutynin Chloride99$4,106
Fesoterodine Fumarate ErFesoterodine Fumarate17$4,048
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst420$3,945
NitrofurantoinNitrofurantoin Macrocrystal93$3,728
Cephalexin60$2,743

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$612$259,350236 claims
Astellas Pharma US IncMyrbetriq$716$164,322191 claims
PfizerPremarin$399$6,52515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 952 urology providers in New York.

Other urology in Garden City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →